14-3-3η Blood Test: A Joint Damage Biomarker
14-3-3η, a clinically proven biomarker for earlier, more accurate RA diagnosis, prognosis and monitoring, is available as a stand alone test at Quest Diagnostics and Labcorp
-
The 14-3-3ƞ blood test is detectable in the pre-clinical phase of arthritis development in patients who are positive for Anti-CCP and/or RF
-
Uncouple inflammation and joint damage: High levels of the 14-3-3ƞ blood test and CRP at baseline and after treatment initiation represent independent predictors of joint damage
-
Achieve radiographic remission and prevent further joint damage by knowing the 14-3-3ƞ levels
-
Treat-to-target: serial decreases in 14-3-3η levels in response to therapy are associated with better clinical outcomes
Quest Diagnostics
HCP Ordering Information
Test code: 91455
LabCorp
HCP Ordering Information
Test code: 504550
Sample Test Report
Publications for health care providers
The 14-3-3η blood test is covered by
CMS and Health Insurance providers
The 14-3-3ƞ blood test is detectable in the pre-clinical phase of arthritis development in patients who are positive for Anti-CCP and/or RF
Uncouple inflammation and joint damage: High levels of the 14-3-3ƞ blood test and CRP at baseline and after treatment initiation represent independent predictors of joint damage
Achieve radiographic remission and prevent further joint damage by knowing the 14-3-3ƞ levels
Treat-to-target: serial decreases in 14-3-3η levels in response to therapy are associated with better clinical outcomes
HCP Ordering Information
Test code: 91455
HCP Ordering Information
Test code: 504550
Sample Test Report
CMS and Health Insurance providers